ContraFect (ContraFect) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 02, 2024)

View and export this data going back to 2014. Start your Free Trial

What is ContraFect Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, ContraFect's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of ContraFect's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, ContraFect's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ContraFect's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where ContraFect's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

ContraFect (OTCPK:CFRXQ) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

ContraFect Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of ContraFect's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

ContraFect (ContraFect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701

Website

https://www.contrafect.com

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

Executives

Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger	officer: VP Finance	238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff	director	1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low	director	EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi	director	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner	officer: SVP Business Development	30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	10 percent owner	BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd	10 percent owner	FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino	officer: Chief Medical Officer	757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos	officer: General Counsel	207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421